BI 1823911

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 1823911, covering 2026-02-17 to 2026-02-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation [Phase 1]

See pricing